Roche‘s (OTC:RHHBY) Genentech reported this week that the FDA approved the subcutaneous formulation of tocilizumab for the treatment of active systemic juvenile idiopathic arthritis in patients two years and older.
The U.S. agency approved the intravenous formulation of Actemra for the same indication in 2011.
Get the full story at our sister site, Drug Delivery Business News.
The post Genentech wins FDA nod for subcutaneous formulation of arthritis drug appeared first on MassDevice.
from MassDevice https://ift.tt/2MuVlCr
Cap comentari:
Publica un comentari a l'entrada